{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T10:14:27Z","timestamp":1783678467955,"version":"3.55.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003093","name":"Ministry of Higher Education, Malaysia","doi-asserted-by":"publisher","award":["FRGS\/1\/2023\/SKK06\/AIMST\/03\/2"],"award-info":[{"award-number":["FRGS\/1\/2023\/SKK06\/AIMST\/03\/2"]}],"id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12122-0","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T09:25:31Z","timestamp":1783675531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of attenuated and inactivated Dengue strains using advanced gene editing tools"],"prefix":"10.1007","volume":"53","author":[{"given":"Ramesh","family":"Thevendran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solayappan","family":"Maheswaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Yin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"12122_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2025.107940","volume":"158","author":"N Haider","year":"2025","unstructured":"Haider N, Hasan MN, Onyango J, Billah M, Khan S, Papakonstantinou D, Paudyal P, Asaduzzaman M (2025) Global dengue epidemic worsens with record 14 million cases and 9000 deaths reported in 2024. Int J Infect Dis 158:107940. https:\/\/doi.org\/10.1016\/j.ijid.2025.107940","journal-title":"Int J Infect Dis"},{"key":"12122_CR2","doi-asserted-by":"crossref","unstructured":"Mwanyika GO, Misinzo G, Rugarabamu S, Sindato C, Mboera L (2019) Challenges and opportunities of laboratory diagnosis of dengue virus infection: a review. Res Sq (Research Square)","DOI":"10.21203\/rs.2.9213\/v1"},{"key":"12122_CR3","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1186\/1471-2458-14-781","volume":"14","author":"M Bouzid","year":"2014","unstructured":"Bouzid M, Col\u00f3n-Gonz\u00e1lez FJ, Lung T, Lake IR, Hunter PR (2014) Climate change and the emergence of vector-borne diseases in Europe: case study of dengue fever. BMC Public Health 14:781. https:\/\/doi.org\/10.1186\/1471-2458-14-781","journal-title":"BMC Public Health"},{"key":"12122_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0012932","author":"WX Zhang","year":"2025","unstructured":"Zhang WX, Zhao TY, Wang CC, He Y, Lu HZ, Zhang HT, Wang LM, Zhang M, Li CX, Deng SQ (2025) Assessing the global dengue burden: incidence, mortality, and disability trends over three decades. PLoS Negl Trop Dis. https:\/\/doi.org\/10.1371\/journal.pntd.0012932","journal-title":"PLoS Negl Trop Dis"},{"key":"12122_CR5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.7150\/ijms.29938","volume":"16","author":"Z Ahmad","year":"2019","unstructured":"Ahmad Z, Poh CL (2019) The conserved molecular determinants of virulence in dengue virus. Int J Med Sci 16:355\u2013365","journal-title":"Int J Med Sci"},{"key":"12122_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104922","volume":"99","author":"A Miauton","year":"2024","unstructured":"Miauton A (2024) Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 study. EBioMedicine 99:104922. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104922","journal-title":"EBioMedicine"},{"key":"12122_CR7","volume-title":"Immune response in dengue fever and clinical implications","author":"M Priyadarshi","year":"2024","unstructured":"Priyadarshi M, Sikdar S, Brijwal M (2024) Immune response in dengue fever and clinical implications. In IntechOpen eBooks, IntechOpen"},{"key":"12122_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.932408","author":"J Bigay","year":"2022","unstructured":"Bigay J (2022) Vaccine-associated enhanced disease in humans and animal models: lessons and challenges for vaccine development. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2022.932408","journal-title":"Front Microbiol"},{"key":"12122_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2101","author":"M Redoni","year":"2020","unstructured":"Redoni M (2020) Dengue: status of current and under-development vaccines. Rev Med Virol. https:\/\/doi.org\/10.1002\/rmv.2101","journal-title":"Rev Med Virol"},{"key":"12122_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.00362","author":"J Sun","year":"2020","unstructured":"Sun J, Du S, Zheng Z, Cheng G, Jin X (2020) Defeat dengue and Zika viruses with a one-two punch of vaccine and vector blockade. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2020.00362","journal-title":"Front Microbiol"},{"key":"12122_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00340-5","author":"AM Bifani","year":"2021","unstructured":"Bifani AM, Choy MM, Tan HC, Ooi EE (2021) Attenuated dengue viruses are genetically more diverse than their respective wild-type parents. npj Vaccines. https:\/\/doi.org\/10.1038\/s41541-021-00340-5","journal-title":"npj Vaccines"},{"key":"12122_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/srep26100","author":"KCM Goh","year":"2016","unstructured":"Goh KCM (2016) Molecular determinants of plaque size as an indicator of dengue virus attenuation. Sci Rep. https:\/\/doi.org\/10.1038\/srep26100","journal-title":"Sci Rep"},{"key":"12122_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-4-39","author":"JE Blaney","year":"2004","unstructured":"Blaney JE (2004) Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2. BMC Infect Dis. https:\/\/doi.org\/10.1186\/1471-2334-4-39","journal-title":"BMC Infect Dis"},{"key":"12122_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002243","author":"CYH Huang","year":"2013","unstructured":"Huang CYH (2013) Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax). PLoS Negl Trop Dis. https:\/\/doi.org\/10.1371\/journal.pntd.0002243","journal-title":"PLoS Negl Trop Dis"},{"key":"12122_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1362780","author":"R Akter","year":"2024","unstructured":"Akter R, Tasneem F, Das S, Soma MA, Georgakopoulos-Soares I, Juthi RT, Sazed SA (2024) Approaches of dengue control: vaccine strategies and future aspects. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2024.1362780","journal-title":"Front Immunol"},{"key":"12122_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152209","author":"D Govindarajan","year":"2016","unstructured":"Govindarajan D, Guan L, Meschino S, Fridman A, Bagchi A, Pak I, Ter Meulen J, Casimiro DR, Bett AJ (2016) A rapid and improved method to generate recombinant dengue virus vaccine candidates. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0152209","journal-title":"PLoS ONE"},{"key":"12122_CR17","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1586\/14760584.2016.1115727","volume":"15","author":"SS Whitehead","year":"2016","unstructured":"Whitehead SS (2016) Development of TV003\/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the sanofi-pasteur CYD\u2122 vaccine? Expert Rev Vaccines 15:509\u2013517","journal-title":"Expert Rev Vaccines"},{"key":"12122_CR18","doi-asserted-by":"publisher","first-page":"7242","DOI":"10.1016\/j.vaccine.2011.07.023","volume":"29","author":"AP Durbin","year":"2011","unstructured":"Durbin AP, Kirkpatrick BD, Pierce KK, Schmidt AC, Whitehead SS (2011) Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine 29:7242\u20137250","journal-title":"Vaccine"},{"key":"12122_CR19","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.vaccine.2007.11.082","volume":"26","author":"JE Blaney","year":"2008","unstructured":"Blaney JE, Sathe NS, Goddard L, Hanson CT, Romero TA, Hanley KA, Murphy BR, Whitehead SS (2008) Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3\u2032 untranslated region (3\u2032-UTR) or by exchange of the DENV-3 3\u2032-UTR with that of DENV-4. Vaccine 26:817\u2013828. https:\/\/doi.org\/10.1016\/j.vaccine.2007.11.082","journal-title":"Vaccine"},{"key":"12122_CR20","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1093\/infdis\/jis936","volume":"207","author":"AP Durbin","year":"2013","unstructured":"Durbin AP, Kirkpatrick BD, Pierce KK, Elwood D, Larsson CJ, Lindow JC, Tibery C, Sabundayo BP, Shaffer D, Talaat KR et al (2013) A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized. Double-Blind Clinical Trial J Infect Dis 207:957\u2013965. https:\/\/doi.org\/10.1093\/infdis\/jis936","journal-title":"Double-Blind Clinical Trial J Infect Dis"},{"key":"12122_CR21","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1586\/14760584.2013.815412","volume":"12","author":"MA McArthur","year":"2013","unstructured":"McArthur MA, Sztein MB, Edelman R (2013) Dengue vaccines: recent developments, ongoing challenges and current candidates. Expert Rev Vaccines 12:933\u2013953","journal-title":"Expert Rev Vaccines"},{"key":"12122_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1011753","author":"WX Chin","year":"2023","unstructured":"Chin WX, Kong HY, Zhu IXY, Teo ZY, Faruk R, Lee RCH, Ho SX, Aw ZQ, Yi B, Hou XJ et al (2023) Flavivirus genome recoding by codon optimisation confers genetically stable in vivo attenuation in both mice and mosquitoes. PLoS Pathog. https:\/\/doi.org\/10.1371\/journal.ppat.1011753","journal-title":"PLoS Pathog"},{"key":"12122_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198303","author":"CB Stauft","year":"2018","unstructured":"Stauft CB, Shen SH, Song Y, Gorbatsevych O, Asare E, Futcher B, Mueller S, Payne A, Brecher M, Kramer L et al (2018) Extensive recoding of dengue virus type 2 specifically reduces replication in primate cells without gain-of-function in aedes aegypti mosquitoes. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0198303","journal-title":"PLoS ONE"},{"key":"12122_CR24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s40588-018-0080-3","volume":"5","author":"N Osterrieder","year":"2018","unstructured":"Osterrieder N, Kunec D (2018) Attenuation of viruses by large-scale recoding of their genomes: the selection is always biased. Curr Clin Microbiol Reports 5:66\u201372","journal-title":"Curr Clin Microbiol Reports"},{"key":"12122_CR25","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.omtn.2020.01.028","volume":"19","author":"H Li","year":"2020","unstructured":"Li H, Wang S, Dong X, Li Q, Li M, Li J, Guo Y, Jin X, Zhou Y, Song H et al (2020) CRISPR-cas13a cleavage of dengue virus NS3 gene efficiently inhibits viral replication. Mol Ther - Nucleic Acids 19:1460\u20131469. https:\/\/doi.org\/10.1016\/j.omtn.2020.01.028","journal-title":"Mol Ther - Nucleic Acids"},{"key":"12122_CR26","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3390\/genes16080875","volume":"16","author":"X Tan","year":"2025","unstructured":"Tan X, Li J, Cui B, Wu J, Toischer K, Hasenfu\u00df G, Xu X (2025) CRISPR\/Cas13-based anti-RNA viral approaches. Genes (Basel) 16:875. https:\/\/doi.org\/10.3390\/genes16080875","journal-title":"Genes (Basel)"},{"key":"12122_CR27","doi-asserted-by":"publisher","first-page":"661","DOI":"10.6026\/97320630018661","volume":"18","author":"A Prajapati","year":"2022","unstructured":"Prajapati A (2022) Towards the diagnosis of dengue virus and its serotypes using designed CRISPR\/Cas13 GRNAs. Bioinformation 18:661\u2013668. https:\/\/doi.org\/10.6026\/97320630018661","journal-title":"Bioinformation"},{"key":"12122_CR28","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1089\/crispr.2021.0017","volume":"4","author":"N Tang","year":"2021","unstructured":"Tang N, Zhang Y, Shen Z, Yao Y, Nair V (2021) Application of CRISPR-Cas9 editing for virus engineering and the development of recombinant viral vaccines. Cris J 4:477\u2013490","journal-title":"Cris J"},{"key":"12122_CR29","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/scibx.2013.942","volume":"6","author":"K Fink","year":"2013","unstructured":"Fink K, Shi P, Qin C (2013) 2\u2032-O-Methyltransferase\u2013deficient, live. Attenuated Dengue Virus Vaccine Sci Exch 6:942\u2013942. https:\/\/doi.org\/10.1038\/scibx.2013.942","journal-title":"Attenuated Dengue Virus Vaccine Sci Exch"},{"key":"12122_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003521","author":"R Z\u00fcst","year":"2013","unstructured":"Z\u00fcst R, Dong H, Li XF, Chang DC, Zhang B, Balakrishnan T, Toh YX, Jiang T, Li SH, Deng YQ et al (2013) Rational design of a live attenuated dengue vaccine: 2\u2032-O-methyltransferase mutants are highly attenuated and immunogenic in mice and macaques. PLoS Pathog. https:\/\/doi.org\/10.1371\/journal.ppat.1003521","journal-title":"PLoS Pathog"},{"key":"12122_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189262","author":"R Z\u00fcst","year":"2018","unstructured":"Z\u00fcst R, Li SH, Xie X, Velumani S, Chng M, Toh YX, Zou J, Dong H, Shan C, Pang J et al (2018) Characterization of a candidate tetravalent vaccine based on 2\u2019-O-methyltransferase mutants. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0189262","journal-title":"PLoS ONE"},{"key":"12122_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002465","author":"AM Pham","year":"2012","unstructured":"Pham AM, Langlois RA, tenOever BR (2012) Replication in cells of hematopoietic origin is necessary for dengue virus dissemination. PLoS Pathog. https:\/\/doi.org\/10.1371\/journal.ppat.1002465","journal-title":"PLoS Pathog"},{"key":"12122_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004852","author":"KA Tsetsarkin","year":"2015","unstructured":"Tsetsarkin KA, Liu G, Kenney H, Bustos-Arriaga J, Hanson CT, Whitehead SS, Pletnev AG (2015) Dual MiRNA targeting restricts host range and attenuates neurovirulence of flaviviruses. PLoS Pathog. https:\/\/doi.org\/10.1371\/journal.ppat.1004852","journal-title":"PLoS Pathog."},{"key":"12122_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/ncrna4040025","volume":"4","author":"EJ Fay","year":"2018","unstructured":"Fay EJ, Langlois RA (2018) MicroRNA-attenuated virus vaccines. Non-coding RNA 4:25","journal-title":"Non-coding RNA"},{"key":"12122_CR35","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1128\/jvi.74.7.3020-3028.2000","volume":"74","author":"CY-H Huang","year":"2000","unstructured":"Huang CY-H, Butrapet S, Pierro DJ, Chang G-JJ, Hunt AR, Bhamarapravati N, Gubler DJ, Kinney RM (2000) Chimeric dengue type 2 (vaccine strain PDK-53)\/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J Virol 74:3020\u20133028. https:\/\/doi.org\/10.1128\/jvi.74.7.3020-3028.2000","journal-title":"J Virol"},{"key":"12122_CR36","doi-asserted-by":"publisher","first-page":"7251","DOI":"10.1016\/j.vaccine.2011.07.020","volume":"29","author":"JE Osorio","year":"2011","unstructured":"Osorio JE, Huang CYH, Kinney RM, Stinchcomb DT (2011) Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine 29:7251\u20137260","journal-title":"Vaccine"},{"key":"12122_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36702-x","author":"E Young","year":"2023","unstructured":"Young E, Yount B, Pantoja P, Henein S, Meganck RM, McBride J, Munt JE, Baric TJ, Zhu D, Scobey T et al (2023) A live dengue virus vaccine carrying a chimeric envelope glycoprotein elicits dual DENV2-DENV4 serotype-specific immunity. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-023-36702-x","journal-title":"Nat Commun"},{"key":"12122_CR38","doi-asserted-by":"publisher","first-page":"640964","DOI":"10.3389\/fmedt.2021.640964","volume":"3","author":"AMB Alves","year":"2021","unstructured":"Alves AMB, Costa SM, Pinto PBA (2021) Dengue virus and vaccines: how can DNA immunization contribute to this challenge? Front Med Technol 3:640964","journal-title":"Front Med Technol"},{"key":"12122_CR39","first-page":"178","volume":"38","author":"E Prompetchara","year":"2020","unstructured":"Prompetchara E, Ketloy C, Thomas SJ, Ruxrungtham K (2020) Dengue vaccine: global development update. Asian Pacific J Allergy Immunol 38:178\u2013185","journal-title":"Asian Pacific J Allergy Immunol"},{"key":"12122_CR40","doi-asserted-by":"publisher","first-page":"1520968","DOI":"10.3389\/fimmu.2025.1520968","volume":"16","author":"X Liu","year":"2025","unstructured":"Liu X (2025) Opportunities and challenges of MRNA technologies in development of dengue virus vaccine. Front Immunol 16:1520968","journal-title":"Front Immunol"},{"key":"12122_CR41","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2528368","volume":"21","author":"C Denani","year":"2025","unstructured":"Denani C (2025) Evolution of the PRNT: merging tradition and innovation to set the gold standard in the era of automation. Hum Vaccin Immunother 21:2528368. https:\/\/doi.org\/10.1080\/21645515.2025.2528368","journal-title":"Hum Vaccin Immunother"},{"key":"12122_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1356600","volume":"15","author":"Y Wang","year":"2024","unstructured":"Wang Y, Troutman MC, Hofmann C, Gonzalez A, Song L, Levin R, Pixley HY, Kearns K, DePhillips P, Loughney JW (2024) fully automated high-throughput immuno-\u03bcplaque assay for live-attenuated tetravalent dengue vaccine development. Front Immunol 15:1356600. https:\/\/doi.org\/10.3389\/fimmu.2024.1356600","journal-title":"Front Immunol"},{"key":"12122_CR43","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1128\/JCM.43.7.3267-3272.2005","volume":"43","author":"CR Lambeth","year":"2005","unstructured":"Lambeth CR, White LJ, Johnston RE, De Silva AM (2005) Flow cytometry-based assay for titrating dengue virus. J Clin Microbiol 43:3267\u20133272. https:\/\/doi.org\/10.1128\/JCM.43.7.3267-3272.2005","journal-title":"J Clin Microbiol"},{"key":"12122_CR44","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1128\/JCM.00827-07","volume":"45","author":"AA Kraus","year":"2007","unstructured":"Kraus AA (2007) Comparison of plaque- and flow cytometry-based methods for measuring dengue virus neutralization. J Clin Microbiol 45:3777\u20133780. https:\/\/doi.org\/10.1128\/JCM.00827-07","journal-title":"J Clin Microbiol"},{"key":"12122_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0297081","author":"A Cerda","year":"2024","unstructured":"Cerda A, Rivera M, Armijo G, Ibarra-Henriquez C, Reyes J, Bl\u00e1zquez-S\u00e1nchez P, Avil\u00e9s J, Arce A, Seguel A, Brown AJ et al (2024) An open one-step RT-QPCR for SARS-CoV-2 detection. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0297081","journal-title":"PLoS ONE"},{"key":"12122_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1048661","author":"PJ Schmidt","year":"2023","unstructured":"Schmidt PJ, Acosta N, Chik AHS, D\u2019Aoust PM, Delatolla R, Dhiyebi HA, Glier MB, Hubert CRJ, Kopetzky J, Mangat CS et al (2023) Realizing the value in \u201cnon-standard\u201d parts of the QPCR standard curve by integrating fundamentals of quantitative microbiology. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2023.1048661","journal-title":"Front Microbiol"},{"key":"12122_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1292467","volume":"14","author":"SP Chaki","year":"2024","unstructured":"Chaki SP (2024) Validating the inactivation of viral pathogens with a focus on SARS-CoV-2 to safely transfer samples from high-containment laboratories. Front Cell Infect Microbiol 14:1292467. https:\/\/doi.org\/10.3389\/fcimb.2024.1292467","journal-title":"Front Cell Infect Microbiol"},{"key":"12122_CR48","doi-asserted-by":"publisher","DOI":"10.1007\/s12560-024-09632-0","volume":"17","author":"RS Mirmahdi","year":"2025","unstructured":"Mirmahdi RS (2025) Navigating uncertainties in RT-QPCR and infectivity assessment of norovirus. Food Environ Virol 17:22. https:\/\/doi.org\/10.1007\/s12560-024-09632-0","journal-title":"Food Environ Virol"},{"key":"12122_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108086","volume":"100","author":"K Shahzamani","year":"2021","unstructured":"Shahzamani K, Mahmoudian F, Ahangarzadeh S, Ranjbar MM, Beikmohammadi L, Bahrami S, Mohammadi E, Esfandyari S, Alibakhshi A, Javanmard SH (2021) Vaccine design and delivery approaches for COVID-19. Int Immunopharmacol 100:108086. https:\/\/doi.org\/10.1016\/j.intimp.2021.108086","journal-title":"Int Immunopharmacol"},{"key":"12122_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113411","author":"S Pal","year":"2014","unstructured":"Pal S, Dauner AL, Mitra I, Forshey BM, Garcia P, Morrison AC, Halsey ES, Kochel TJ, Wu SJL (2014) Evaluation of dengue Ns1 antigen rapid tests and Elisa kits using clinical samples. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0113411","journal-title":"PLoS ONE"},{"key":"12122_CR51","doi-asserted-by":"publisher","first-page":"20063","DOI":"10.1073\/pnas.1012537107","volume":"107","author":"A Neverov","year":"2010","unstructured":"Neverov A, Chumakov K (2010) Massively parallel sequencing for monitoring genetic consistency and quality control of live viral vaccines. Proc Natl Acad Sci U S A 107:20063\u201320068. https:\/\/doi.org\/10.1073\/pnas.1012537107","journal-title":"Proc Natl Acad Sci U S A"},{"key":"12122_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-020-05317-8","volume":"20","author":"Y Nakaya","year":"2020","unstructured":"Nakaya Y (2020) Quick assessment of influenza a virus infectivity with a long-range reverse-transcription quantitative polymerase chain reaction assay. BMC Infect Dis 20:585. https:\/\/doi.org\/10.1186\/s12879-020-05317-8","journal-title":"BMC Infect Dis"},{"key":"12122_CR53","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12866-022-02723-7","volume":"22","author":"M Yasuura","year":"2022","unstructured":"Yasuura M (2022) Investigation on the applicability of a long-range reverse-transcription quantitative polymerase chain reaction assay for the rapid detection of active viruses. BMC Microbiol 22:300. https:\/\/doi.org\/10.1186\/s12866-022-02723-7","journal-title":"BMC Microbiol"},{"key":"12122_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.mex.2022.101737","volume":"9","author":"P Gregorova","year":"2022","unstructured":"Gregorova P, Heinonen MMK, Sarin LP (2022) An improved RT-QPCR method for direct quantification of enveloped RNA viruses. MethodsX 9:101737. https:\/\/doi.org\/10.1016\/j.mex.2022.101737","journal-title":"MethodsX"},{"key":"12122_CR55","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3389\/fimmu.2014.00452","volume":"5","author":"CA Sariol","year":"2014","unstructured":"Sariol CA, White LJ (2014) Utility, limitations, and future of non-human primates for dengue research and vaccine development. Front Immunol 5:452","journal-title":"Front Immunol"},{"key":"12122_CR56","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1016\/j.vaccine.2010.04.045","volume":"28","author":"MC Cassetti","year":"2010","unstructured":"Cassetti MC, Durbin A, Harris E, Rico-Hesse R, Roehrig J, Rothman A, Whitehead S, Natarajan R, Laughlin C (2010) Report of an NIAID workshop on dengue animal models. Vaccine 28:4229\u20134234. https:\/\/doi.org\/10.1016\/j.vaccine.2010.04.045","journal-title":"Vaccine"},{"key":"12122_CR57","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12985-015-0444-8","volume":"12","author":"T Nedjadi","year":"2015","unstructured":"Nedjadi T, El-Kafrawy S, Sohrab SS, Despr\u00e8s P, Damanhouri G, Azhar E (2015) Tackling dengue fever: current status and challenges positive-strand RNA viruses. Virol J 12:212","journal-title":"Virol J"},{"key":"12122_CR58","doi-asserted-by":"publisher","first-page":"440","DOI":"10.18433\/jpps30216","volume":"22","author":"M Jasamai","year":"2019","unstructured":"Jasamai M, Boon YW, Sakulpanich A, Jaleel A (2019) Current prevention and potential treatment options for dengue infection. J Pharm Pharm Sci 22:440\u2013456","journal-title":"J Pharm Pharm Sci"},{"key":"12122_CR59","doi-asserted-by":"crossref","unstructured":"Coronel-ruiz C, Guti H, Medina-moreno S (2020) Humanized mice in dengue research\u202f: a comparison with other mouse models:1\u201323.","DOI":"10.3390\/vaccines8010039"},{"key":"12122_CR60","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/diseases12010029","volume":"12","author":"IS Horbach","year":"2024","unstructured":"Horbach IS, de Souza AA, Schwarcz WD, dos Alves s NS, de Moura DB, Setatino BP, da Cruz ML, de Souza AF, Denani CB, da Silva SA et al (2024) Plaque Reduction Neutralization Test (PRNT) accuracy in evaluating humoral immune response to SARS-CoV-2. Diseases 12:29. https:\/\/doi.org\/10.3390\/diseases12010029","journal-title":"Diseases"},{"key":"12122_CR61","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1089\/vim.2008.0007","volume":"21","author":"JT Roehrig","year":"2008","unstructured":"Roehrig JT, Hombach J, Barrett ADT (2008) Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 21:123\u2013132","journal-title":"Viral Immunol"},{"key":"12122_CR62","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/978-1-4939-8567-8_15","volume":"1808","author":"GN Malavige","year":"2018","unstructured":"Malavige GN (2018) Ex Vivo ELISpot assay to investigate dengue virus specific T-Cell responses. Methods Mol Biol 1808:173\u2013179. https:\/\/doi.org\/10.1007\/978-1-4939-8567-8_15","journal-title":"Methods Mol Biol"},{"key":"12122_CR63","doi-asserted-by":"publisher","first-page":"27850","DOI":"10.3390\/ijms161126069","volume":"16","author":"YL Tang","year":"2015","unstructured":"Tang YL, Chiu CY, Lin CY, Huang CH, Chen YH, Destura RV, Chao DY, Wu HC (2015) Establishment and comparison of two different diagnostic platforms for detection of DENV1 NS1 protein. Int J Mol Sci 16:27850\u201327864. https:\/\/doi.org\/10.3390\/ijms161126069","journal-title":"Int J Mol Sci"},{"key":"12122_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00537-2","author":"H Friberg","year":"2022","unstructured":"Friberg H, Gargulak M, Kong A, Lin L, Martinez LJ, Schmidt AC, Paris RM, Jarman RG, Diaz C, Thomas SJ et al (2022) Characterization of B-Cell and T-Cell responses to a tetravalent dengue purified inactivated vaccine in healthy adults. npj Vaccines. https:\/\/doi.org\/10.1038\/s41541-022-00537-2","journal-title":"npj Vaccines"},{"key":"12122_CR65","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1080\/21645515.2019.1581536","volume":"15","author":"P Moris","year":"2019","unstructured":"Moris P, Bauer KM, Currier JR, Friberg H, Eckels KH, Esquilin IO, Gibbons RV, Innis BL, Jarman RG, Simasathien S et al (2019) Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions. Hum Vaccines Immunother 15:2090\u20132105. https:\/\/doi.org\/10.1080\/21645515.2019.1581536","journal-title":"Hum Vaccines Immunother"},{"key":"12122_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/srep34215","author":"G Swaminathan","year":"2016","unstructured":"Swaminathan G, Thoryk E, Cox KS, Smith JS, Wolf J, Gindy ME, Casimiro DR, Bett AJ (2016) A tetravalent sub-unit dengue vaccine formulated with ionizable cationic lipid nanoparticle induces significant immune responses in rodents and non-human primates. Sci Rep. https:\/\/doi.org\/10.1038\/srep34215","journal-title":"Sci Rep"},{"key":"12122_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1128784","author":"CC Aggarwal","year":"2023","unstructured":"Aggarwal CC, Ramasamy V, Garg A, Shukla R, Khanna N (2023) Cellular T-Cell immune response profiling by tetravalent Dengue Subunit Vaccine (DSV4) candidate in mice. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1128784","journal-title":"Front Immunol"},{"key":"12122_CR68","doi-asserted-by":"publisher","DOI":"10.1128\/msphere.00671-19","author":"H Friberg","year":"2020","unstructured":"Friberg H, Martinez LJ, Lin L, Blaylock JM, De La Barrera RA, Rothman AL, Putnak JR, Eckels KH, Thomas SJ, Jarman RG et al (2020) Cell-mediated immunity generated in response to a purified inactivated vaccine for dengue virus type. MSphere. https:\/\/doi.org\/10.1128\/msphere.00671-19","journal-title":"MSphere"},{"key":"12122_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(09)70290-2","author":"B Guy","year":"2009","unstructured":"Guy B (2009) Immunogenicity of sanofi pasteur tetravalent dengue vaccine. J Clin Virol. https:\/\/doi.org\/10.1016\/S1386-6532(09)70290-2","journal-title":"J Clin Virol"},{"key":"12122_CR70","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s40259-022-00531-z","volume":"36","author":"JM Torres-Flores","year":"2022","unstructured":"Torres-Flores JM, Reyes-Sandoval A, Salazar MI (2022) Dengue vaccines: an update. BioDrugs 36:325\u2013336","journal-title":"BioDrugs"},{"key":"12122_CR71","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3390\/v17020212","volume":"17","author":"G Anumanthan","year":"2025","unstructured":"Anumanthan G, Sahay B, Mergia A (2025) Current dengue virus vaccine developments and future directions. Viruses 17:212","journal-title":"Viruses"},{"key":"12122_CR72","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1038\/s41564-024-01726-6","volume":"9","author":"M Basu","year":"2024","unstructured":"Basu M, Zurla C, Auroni TT, Vanover D, Chaves LCS, Sadhwani H, Pathak H, Basu R, Beyersdorf JP, Amuda OO et al (2024) MRNA-encoded cas13 can be used to treat dengue infections in mice. Nat Microbiol 9:2160\u20132172. https:\/\/doi.org\/10.1038\/s41564-024-01726-6","journal-title":"Nat Microbiol"},{"key":"12122_CR73","doi-asserted-by":"publisher","first-page":"a030700","DOI":"10.1101\/cshperspect.a030700","volume":"10","author":"SB Halstead","year":"2018","unstructured":"Halstead SB (2018) Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination?: there is only one true winner. Cold Spring Harb Perspect Biol 10:a030700","journal-title":"Cold Spring Harb Perspect Biol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12122-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12122-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12122-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T09:25:34Z","timestamp":1783675534000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12122-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12122"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12122-0","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"15 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NA","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"AI was used to improve overall readability, language, and grammatical errors for international standards.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Use of AI in manuscript writing"}}],"article-number":"1144"}}